Other Mutations: BRCA+

NCT05417594: Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies

NCT05417594
Breast Cancer Type: HR+ & HER2-negative
Hormone Mutations: ER+, PR+
Other Mutations: BRCA+, DNA damage repair mutations,
Breast Cancer Tissue: 
Recruitment Status: Not yet recruiting
Phase 1|Phase 2
Drug Category: Misc Inhibitor, Chemotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 130 Years (Adult, Older Adult)
Location of Metastases: Brain
Additional Notes: 
Exclusions: Breast cancer patients are only eligible for Module 1 Parts A & B
https://ClinicalTrials.gov/show/NCT05417594

NCT05144698: RAPA-201 Therapy of Solid Tumors

NCT05144698
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: BRAF, ALK, BRCA+, EGFR
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Immunotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patient must have exposure to an anti-PD-(L)1 therapeutic monoclonal antibody therapeutic in the most recent line of prior therapy (e.g. Keytruda/pembrolizumab, Tecentriq/atezolizumab)
Exclusions: Patients with cancer metastasis to the central nervous system, unless adequately treated
https://ClinicalTrials.gov/show/NCT05144698

Up ↑